Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
858
Views
13
CrossRef citations to date
0
Altmetric
Letter to the Editor

Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib

Kaelyn C. Cumminsa Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; ;b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
,
Matthew P. Chenga Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; ;b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ;c Harvard Medical School, Boston, MA, USACorrespondence[email protected]
,
David W. Kubiakb Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ;c Harvard Medical School, Boston, MA, USA
,
Matthew S. Davidsb Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ;c Harvard Medical School, Boston, MA, USA
,
Francisco M. Martya Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; ;b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ;c Harvard Medical School, Boston, MA, USA
&
Nicolas C. Issaa Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; ;b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ;c Harvard Medical School, Boston, MA, USA
Pages 527-530 | Received 06 Apr 2018, Accepted 27 May 2018, Published online: 24 Jul 2018

References

  • Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood. 2002;100:3741–3748.
  • Yan Q, Huang Y, Watkins AJ, et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica. 2012;97:595–598.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
  • Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
  • Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid malignancies. Clin Infect Dis. 2018. [March 1]. doi:10.1093/cid/ciy175.
  • Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833–843.e5.
  • Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–e60.
  • Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother. 2008;61 (suppl. 1):i19–i30. DOI:10.1093/jac/dkm428.
  • Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet (London, England). 2016;387:760–769.
  • Marty FM, Ostrosky ZL, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837.
  • De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821.
  • Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124:3991–3995.
  • Tisi MC, Hohaus S, Cuccaro A, et al. Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study. Haematologica. 2017;102:e108–e111.
  • Akinleye A, Avvaru P, Furqan M, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6:88.
  • Bodur C, Basaga H. Bcl-2 inhibitors: emerging drugs in cancer therapy. Curr Med Chem. 2012;19:1804–1820.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.